A nationwide German registry study of more than 16,000 diffuse large B-cell lymphoma patients found that later initiation of ...
A Chinese genetic association study links inherited variants in lipid metabolism genes to the risk, severity, treatment ...
AbbVie and Genmab’s bispecific antibody blew analyst expectations out of the water with a 51% improvement in progression-free survival when used alongside a standard frontline regimen in diffuse large ...
The trial met its primary end point of progression-free survival in patients with an International Prognostic Index (IPI) ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Jeremy S. Abramson, MD, discusses 2-year results from the phase 3 STARGLO trial, which ...
– Updated data from the pivotal Phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who are ...
Company Announcement COPENHAGEN, Denmark and NORTH CHICAGO, Ill.; October 5, 2026 EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically ...
Why do outcomes differ even when patients receive the same treatment?Even when patients are diagnosed with the same condition ...
Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within the ...
Diffuse large B-cell lymphoma is a common type of non-Hodgkin’s lymphoma that also has a high rate of relapse. Common signs of a relapse include lymph node swelling, as well as the development of “B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results